MedPath

Psychophysiological Effects of Lactobacillus Plantarum PS128 in Preschool Children With Autism Spectrum Disorder

Not Applicable
Conditions
Autism
Registration Number
NCT03982290
Lead Sponsor
Mackay Memorial Hospital
Brief Summary

Autism Spectrum Disorders (ASD) comprises a complex group of disorders of neuronal development characterized by social and communication impairment along with presence of repetitive and restrictive behaviors. Emerging evidences support the gut-brain axis and further microbiota-gut-brain axis. Elevated prevalence of gastrointestinal (GI) dysfunction in individuals with ASD suggested that targeting gut may benefit patients with ASD. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal studies which modulated the levels of neurotransmitters in different brain areas. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in preschool children with ASD.

Detailed Description

Emerging evidences support the gut-brain axis and further microbiota-gut-brain axis. Elevated prevalence of gastrointestinal (GI) dysfunction in individuals with ASD suggested that targeting gut may benefit patients with ASD. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal studies which modulated the levels of neurotransmitters in different brain areas. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in preschool children with ASD.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Fulfill Diagnostic and Statistical Manual of Mental Disorders fifth version (DSM-V) criteria of Autism Spectrum Disorder
  • Do not take any other probiotics for at least 3 weeks before and during the study period
Exclusion Criteria
  • Autistic children with other neurodevelopmental disorders or psychiatric diseases
  • With a clinically significant chronic medical condition, including; anemia, brain malformations, metabolic diseases, epilepsy, organic gastrointestinal disorders (i.e. gastroesophageal reflux, food allergies, irritable bowel syndrome (IBS)) and Celiac disease
  • On anti-fungal, antibiotics, special diet (i.e. gluten-free diet, casein-free diet, high-protein diet, ketogenic diet) and current use of psychiatric medications within the preceding 3 weeks were excluded
  • Known allergy to probiotics

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Changes from hyperactivity subscale of Attention-Deficit/Hyperactivity Disorder Test (ADHDT) at week 8 and week 16Baseline, week 8 and week 16

Inattention, hyperactive symptoms evaluation

Changes from baseline of anxiety subscale in Children's Behavior Checklist (CBCL)/Achenbach System of Empirically Based Assessment (ASEBA) at week 8 and week 16Baseline, week 8 and week 16

ASEBA for behavioral assessment

Secondary Outcome Measures
NameTimeMethod
Change of total scores at week 8 and week 16 from baseline of Penn Interactive Peer Play Scale, (PIPPS)Baseline, week 8 and week 16

PIPPS for communicative and interactive assessment

Change of total scores at week 8 and week 16 from baseline of Social Interaction Assessment ScaleBaseline, week 8 and week 16

Communicative and interactive assessment

Gastrointestinal symptoms recorded by using GI Severity Index (6-GSI) at week 8 and week 16Baseline, week 8 and week 16

constipation, diarrhea, stool consistency, stool smell, flatulence, and abdominal pain

Change of total scores at week 8 and week 16 from baseline of Changes of Childhood Asperger Syndrome Test (CAST)Baseline, week 8 and week 16

CAST for behavioral assessment

Comparison of Microbiota composition between week 8 and baselineBaseline and week 8

Gut and oral microbiota analysis

Trial Locations

Locations (1)

Department of Pediatric Neurology, MacKay Children's Hospital

🇨🇳

Taipei, Taiwan

Department of Pediatric Neurology, MacKay Children's Hospital
🇨🇳Taipei, Taiwan
Hui-Ju Chen
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.